1. Home
  2. FN vs BBIO Comparison

FN vs BBIO Comparison

Compare FN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fabrinet

FN

Fabrinet

HOLD

Current Price

$480.61

Market Cap

14.9B

Sector

Utilities

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$73.73

Market Cap

14.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FN
BBIO
Founded
1999
2015
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9B
14.4B
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
FN
BBIO
Price
$480.61
$73.73
Analyst Decision
Buy
Strong Buy
Analyst Count
7
19
Target Price
$428.83
$74.79
AVG Volume (30 Days)
607.0K
2.1M
Earning Date
11-03-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
14.80
N/A
EPS
9.70
N/A
Revenue
$3,593,227,000.00
$353,780,000.00
Revenue This Year
$30.96
$128.44
Revenue Next Year
$17.15
$76.14
P/E Ratio
$49.32
N/A
Revenue Growth
19.71
62.46
52 Week Low
$148.55
$25.34
52 Week High
$498.00
$75.04

Technical Indicators

Market Signals
Indicator
FN
BBIO
Relative Strength Index (RSI) 63.80 71.15
Support Level $425.29 $71.16
Resistance Level $465.30 $75.04
Average True Range (ATR) 23.60 2.48
MACD 4.45 0.27
Stochastic Oscillator 94.76 88.13

Price Performance

Historical Comparison
FN
BBIO

About FN Fabrinet

Fabrinet provides advance-level optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advance optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advance-level of packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: